Warren Eric, Chief Commercial Officer of Esperion Therapeutics ($ESPR), made two open market sales of company shares over the past year, totaling $3,723. His most recent sale occurred on April 17, 2025. These sales rank 11,439th among 11,678 individual insiders in our database by value sold, far below the average of $8.6 million across 6.4 transactions per insider. Warren Eric recorded no open market purchases in the last 365 days.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 17, 2025 | Esperion Therapeutics, Inc. | $ESPR | Warren Eric | Chief Commercial Officer | S | Common Stock | 108 | $0.98 | 370,218.0000 | 197,848,886 | 0.03% | 0.00% |
| March 18, 2025 | Esperion Therapeutics, Inc. | $ESPR | Warren Eric | Chief Commercial Officer | S | Common Stock | 2433 | $1.49 | 370,326.0000 | 197,848,886 | 0.65% | 0.00% |
| March 14, 2025 | Esperion Therapeutics, Inc. | $ESPR | Warren Eric | Chief Commercial Officer | A | Common Stock | 213000 | $0.00 | 372,759.0000 | 197,848,886 | 133.33% | 0.11% |
| March 14, 2025 | Esperion Therapeutics, Inc. | $ESPR | Warren Eric | Chief Commercial Officer | A | Stock Option (right to buy) | 191000 | $0.00 | 191,000.0000 | 197,848,886 | 9999.99% | 0.10% |
| Feb. 19, 2025 | Esperion Therapeutics, Inc. | $ESPR | Warren Eric | Chief Commercial Officer | S | Common Stock | 239 | $1.87 | 159,759.0000 | 0 | 0.15% | 0.00% |
| Jan. 17, 2025 | Esperion Therapeutics, Inc. | $ESPR | Warren Eric | Chief Commercial Officer | S | Common Stock | 123 | $2.26 | 159,998.0000 | 0 | 0.08% | 0.00% |
| Dec. 17, 2024 | Esperion Therapeutics, Inc. | $ESPR | Warren Eric | Chief Commercial Officer | S | Common Stock | 2234 | $2.43 | 160,121.0000 | 0 | 1.38% | 0.00% |
| Nov. 19, 2024 | Esperion Therapeutics, Inc. | $ESPR | Warren Eric | Chief Commercial Officer | S | Common Stock | 197 | $2.17 | 162,355.0000 | 0 | 0.12% | 0.00% |
| Oct. 17, 2024 | Esperion Therapeutics, Inc. | $ESPR | Warren Eric | Chief Commercial Officer | S | Common Stock | 107 | $2.12 | 162,552.0000 | 0 | 0.07% | 0.00% |
| Sept. 17, 2024 | Esperion Therapeutics, Inc. | $ESPR | Warren Eric | Chief Commercial Officer | S | Common Stock | 2608 | $1.78 | 162,659.0000 | 0 | 1.58% | 0.00% |
| Aug. 19, 2024 | Esperion Therapeutics, Inc. | $ESPR | Warren Eric | Chief Commercial Officer | S | Common Stock | 211 | $1.95 | 165,267.0000 | 0 | 0.13% | 0.00% |
| July 17, 2024 | Esperion Therapeutics, Inc. | $ESPR | Warren Eric | Chief Commercial Officer | S | Common Stock | 108 | $2.59 | 165,478.0000 | 0 | 0.07% | 0.00% |
| June 18, 2024 | Esperion Therapeutics, Inc. | $ESPR | Warren Eric | Chief Commercial Officer | S | Common Stock | 2540 | $2.86 | 165,586.0000 | 0 | 1.51% | 0.00% |
| May 17, 2024 | Esperion Therapeutics, Inc. | $ESPR | Warren Eric | Chief Commercial Officer | S | Common Stock | 192 | $2.48 | 168,126.0000 | 0 | 0.11% | 0.00% |
| March 14, 2024 | Esperion Therapeutics, Inc. | $ESPR | Warren Eric | Chief Commercial Officer | A | Common Stock | 100000 | $0.00 | 168,318.0000 | 0 | 146.37% | 0.00% |
| March 14, 2024 | Esperion Therapeutics, Inc. | $ESPR | Warren Eric | Chief Commercial Officer | A | Stock Option (right to buy) | 150000 | $0.00 | 150,000.0000 | 0 | 9999.99% | 0.00% |